Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 3OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Lymphoid 1

Conditions

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE 1Lymphoma, T-Cell, Peripheral 1

Interventions

Cisplatin 50Capecitabine 42apatinib 34Radiotherapy 33Oxaliplatin 33Gemcitabine 33Cyclophosphamide 32Drug Therapy 31Paclitaxel 30Carboplatin 29tislelizumab 27Irinotecan 27Fluorouracil 26Docetaxel 26Bevacizumab 23Surgical Procedures, Operative 21Nivolumab 19pembrolizumab 18fludarabine 18Metformin 16Exercise 16camrelizumab 15Radiation 15S 1 (combination) 14Control Groups 14Blood Specimen Collection 14Pemetrexed 13Standard of Care 12anlotinib 11Neoadjuvant Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × ivarmacitinib × Clear all
NCT07313202 2025-12-31

Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance

Fujian Cancer Hospital

Phase 2 Not yet recruiting
72 enrolled
Other solid neoplasm

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE

NCT05900089 2023-06-12

Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

Henan Cancer Hospital

Phase 1 Unknown
30 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡